At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 220 enrolled
Drug / intervention
Aspirin 81 mg +1 moredrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida: An Open Label, Comparative Effectiveness, Randomized Controlled Trial (ASPREO Trial)
The University of Texas Health Science Center, Houston·interventional·Posted May 23, 2019·Updated May 8, 2024
In Brief
A Phase 3 clinical trial evaluating Aspirin 81 mg and Aspirin 162 mg for Pre-Eclampsia and 2 related conditions. Completed, enrolled 220 participants across 1 site.
Detailed Summary
To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either 81mg/day aspirin or 162mg/day aspirin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPre-Eclampsia, Hypertension in Pregnancy, Obesity
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedMay 2019
Primary CompletionApr 2023
TodayJul 2026
First PostedMay 23, 2019
Enrollment StartMay 6, 2019
Primary CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.1 years ago
Interventions
Aspirin 81 mgdrug
Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
Aspirin 162 mgdrug
Low dose aspirin was initially reported as having a beneficial effect at preeclampsia